NYSE:BIOLife Sciences
A Look At Bio-Rad (BIO) Valuation After Q1 2026 Net Loss And Outlook Cut
Bio-Rad Laboratories (BIO) stock is in focus after Q1 2026 results showed sales of US$592.1 million and a net loss of US$527.1 million, alongside weaker bioprocessing demand and cautious biotech spending.
See our latest analysis for Bio-Rad Laboratories.
The Q1 2026 net loss and reduced revenue outlook have been followed by a 7 day share price return of 8.14% decline and a year to date share price return of 15.71% decline, while the 1 year total shareholder return of 6.76% suggests longer...